Expertscape, a web platform that identifies and objectively ranks physicians and researchers that excel in the treatment and diagnosis of specific disease states, has released their rankings for US physicians who specialize in breast cancer. Using Expertscape’s patented algorithm, Hope Rugo, MD, of University of California San Francisco Helen Diller Family Comprehensive Cancer Center, is…
Adding ribociclib to letrozole significantly prolonged progression-free survival compared with letrozole alone in postmenopausal women.
Short-term pre-operative treatment with palbociclib significantly reduced Ki67 in treatment-naïve patients with early-stage breast cancer.
Ado-trastuzumab emtansine in combination with docetaxel with or without pertuzumab appeared efficacious in breast cancer.
No association between early use of any supportive medications and end-of-life care among Medicare beneficiaries with advanced breast cancer.
Patients with early breast cancer experienced a pathologic complete response rate with nab-paclitaxel compared with paclitaxel.
An expert ASCO panel identified 9 biomarker tests that may help guide decisions on adjuvant systemic therapy for certain patients with breast cancer.
The FDA approved palbociclib (Ibrance) in combination with fulvestrant for the treatment of patients with breast cancer.
Treatment with abiraterone acetate plus prednisone was beneficial for some patients with molecular apocrine breast cancer.
Patients with metastatic cancer who continue to work may need the income or access to health insurance or simply have the desire to work, yet they face a number of hurdles.
